Department of Basic and Applied Science for Engineering, Sapienza University of Rome, Via A. Scarpa 16, 00161, Rome, Italy.
IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
Anal Bioanal Chem. 2020 May;412(14):3509-3517. doi: 10.1007/s00216-020-02643-3. Epub 2020 Apr 16.
We report on the combined label-free/fluorescence use of one-dimensional photonic crystals to optimize cancer biomarker detection in complex biological media. The optimization of the assay working parameters permits us to maximize the final response of the biosensor. The detection approach utilizes a sandwich assay, in which one-dimensional photonic crystals sustaining Bloch surface waves are modified with monoclonal antibodies in order to guarantee high specificity during biological recognition. The multiple outcomes generated by such optimization experiments permitted us to determine the effective capture efficiency and the repeatability of the immobilization process, which was estimated to be close to 5%. By exploiting the resolution of the fluorescence operation mode, we studied non-specific interactions in different blocking agents, different analyte diluting buffers, and diverse concentrations of the detection antibody. As a clinically relevant biomarker, we selected the trans-membrane receptor tyrosine kinase HER2. HER2 regulates a variety of cell proliferation, growth, and differentiation pathways and its over-expression occurs in approximately 20-30% of breast cancer worldwide. As a final application, we transferred all the optimized working parameters to HER2 cancer biomarker assays in a complex biological environment. The label-free and fluorescence results obtained by analyzing MCF-7 (HER2 low positive) and 32D (HER2 negative) cell lysates demonstrate that we can successfully discriminate the two lysates.
我们报告了一维光子晶体的无标记/荧光联合使用,以优化复杂生物介质中癌症生物标志物的检测。该测定方法的优化使得我们能够最大限度地提高生物传感器的最终响应。该检测方法利用夹心测定法,其中一维光子晶体维持布洛赫表面波,并用单克隆抗体进行修饰,以保证在生物识别过程中的高特异性。通过这种优化实验生成的多种结果,我们确定了有效捕获效率和固定化过程的可重复性,其估计接近 5%。通过利用荧光操作模式的分辨率,我们研究了不同的封闭剂、不同的分析物稀释缓冲液和不同浓度的检测抗体中的非特异性相互作用。作为一种临床相关的生物标志物,我们选择了跨膜受体酪氨酸激酶 HER2。HER2 调节多种细胞增殖、生长和分化途径,其在全球约 20-30%的乳腺癌中过度表达。作为最终的应用,我们将所有优化的工作参数转移到复杂的生物环境中的 HER2 癌症生物标志物测定中。通过分析 MCF-7(HER2 低度阳性)和 32D(HER2 阴性)细胞裂解物的无标记和荧光结果,我们可以成功区分两种裂解物。